



Cancer Incidence Rates, 2016-2020 per 100,000 population by site and gender

Vermont Cancer Registry

August 2023

Male and Female					Male					Female				
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Cases (per year)
All Sites	442.2	469.1	454.7 ▲▼	3,957	All Sites	480.4	508.8	480.8 ▼	2,015	All Sites	416.4	443.9	438.7 ▲	1,941
Lung and Bronchus	54.2	56.8	56.2	519	Prostate	110.2	122.6	101.8 ▼▼	477	Breast	126.9	134.3	131.8	570
Melanoma of the Skin	22.4	20.2	36.6 ▲	302	Lung and Bronchus	61.3	62.2	60.8	263	Lung and Bronchus	48.8	53.1	52.8 ▲	256
Colon and Rectum	36.6	36.4	33.2 ▼▼	282	Melanoma of the Skin	28.5	25.5	42.3 ▲▲	170	Uterus	27.4	31.1	32.6 ▲	159
Urinary Bladder	18.9	22.1	23.0 ▲	209	Colon and Rectum	41.7	41.6	38.8	154	Melanoma of the Skin	18.0	16.5	32.4 ▲▲	133
Non-Hodgkin Lymphoma	18.6	20.4	18.6 ▼	162	Urinary Bladder	32.6	38.1	38.5 ▲	159	Colon and Rectum	32.1	32.1	28.1 ▼▼	128
Kidney	17.2	16.5	16.2	138	Non-Hodgkin Lymphoma	22.4	24.5	23.0	92	Thyroid	19.4	24.9	21.1 ▼	69
Thyroid	13.3	17.2	14.0 ▼	95	Kidney	23.4	23.1	21.5	87	Non-Hodgkin Lymphoma	15.4	17.0	15.0 ▼	70
Leukemia	13.9	14.9	12.7 ▼	104	Oral Cavity/Throat	18.1	17.6	19.5	82	Pancreas	11.7	12.7	12.1	58
Pancreas	13.2	14.3	12.7 ▼	115	Leukemia	17.7	19.2	15.7 ▼	61	Kidney	11.8	10.9	11.5	51
Oral Cavity/Throat	11.9	11.8	12.6	110	Pancreas	15.1	16.3	13.6 ▼	57	Urinary Bladder	8.1	10.0	10.2 ▲	50
Brain/Nervous System	6.4	6.8	7.4 ▲	56	Esophagus	7.8	8.3	9.3 ▲	40	Leukemia	10.9	11.6	10.1	43
Myeloma	7.0	7.4	6.1 ▼	54	Brain/Nervous System	7.5	8.1	8.8	32	Ovary	10.1	10.7	8.6 ▼	38
Liver	8.5	8.3	6.0 ▼▼	57	Liver	12.9	12.8	8.8 ▼▼	41	Oral Cavity/Throat	6.5	6.7	6.3	27
Stomach	6.2	7.1	5.9 ▼	50	Testis	5.8	6.2	8.4 ▲▲	24	Brain/Nervous System	5.3	5.7	6.2	23
Esophagus	4.5	4.8	5.5 ▲	51	Stomach	8.3	9.6	8.0 ▼	33	Cervix	7.6	6.8	5.3 ▼	18
Larynx	3.0	2.9	3.0	27	Myeloma	8.5	9.1	7.5	31	Myeloma	5.7	6.0	5.0	24
Hodgkin Lymphoma	2.6	3.0	2.8	19	Thyroid	7.0	9.3	7.0 ▼	26	Stomach	4.5	5.1	3.9 ▼	17
					Larynx	5.1	5.1	4.6	20	Liver	4.8	4.5	3.4 ▼▼	16
					Hodgkin Lymphoma	2.9	3.4	3.0	10	Hodgkin Lymphoma	2.3	2.7	2.6	9
										Esophagus	1.7	1.9	2.1	11
										Larynx	1.2	1.2	1.6	7

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

TECHNICAL NOTES: Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Incidence rates exclude in situ carcinomas except urinary bladder. Incidence data were coded using the International Classification of Disease for Oncology (ICD-O) coding system. Vermont cases include Vermont residents only. The Vermont and U.S. incidence rates are based on the Vermont Cancer Registry, Vermont Department of Health (1994-2020) and the NPCR and SEER Incidence - U.S. Cancer Statistics Public Use Database, 2021 submission (2001-2020), United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2023. Available at www.cdc.gov/cancer/uscs/public-use. Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont. A reporting delay by Department of Veterans Affairs (VA) has resulted in incomplete reporting of VA hospital cases in 2011-2014, 2016-2020.

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Incidence Rates, 2016-2020, Vermont Department of Health, Burlington, VT, 2023.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement NU58DP007149, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.



Cancer Mortality Rates, 2016-2020 per 100,000 population by site and gender

Vermont Cancer Registry

August 2023

Male and Female					Male					Female				
Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)	Cancer Site	U.S. Rate (All Races)	N.E. Rate (All Races)	VT Rate (All Races)	VT Deaths (per year)
All Sites	149.4	145.5	155.8 ▲ ▲	1,391	All Sites	177.5	172.4	184.2 ▲ ▲	741	All Sites	128.7	126.8	134.3 ▲ ▲	649
Lung and Bronchus	35.0	33.5	36.2 ▲	331	Lung and Bronchus	42.2	39.7	41.4 ▲	174	Lung and Bronchus	29.3	29.0	32.1 ▲ ▲	157
Colon and Rectum	13.1	12.2	14.1 ▲	122	Prostate	18.8	17.8	21.1 ▲ ▲	79	Breast	19.6	18.6	16.4 ▼ ▼	79
Pancreas	11.1	11.4	11.0	101	Colon and Rectum	15.7	14.5	15.7	62	Colon and Rectum	11.0	10.4	12.7 ▲ ▲	60
Leukemia	6.0	5.9	5.9	50	Pancreas	12.7	13.1	11.8	50	Pancreas	9.6	9.9	10.3	51
Non-Hodgkin Lymphoma	5.1	5.1	5.7	49	Esophagus	6.7	7.1	9.2 ▲ ▲	40	Uterus	5.1	5.6	6.3 ▲	31
Brain/Nervous System	4.4	4.4	5.6 ▲ ▲	46	Liver	9.6	8.9	8.1	36	Ovary	6.3	6.4	5.8	28
Liver	6.6	6.0	5.5 ▼	51	Urinary Bladder	7.1	7.4	8.1	31	Leukemia	4.5	4.4	4.7	22
Esophagus	3.8	4.0	5.1 ▲ ▲	48	Non-Hodgkin Lymphoma	6.7	6.7	7.5	28	Brain/Nervous System	3.6	3.4	4.6 ▲ ▲	21
Urinary Bladder	4.2	4.3	4.6	41	Leukemia	8.0	8.0	7.4	28	Non-Hodgkin Lymphoma	3.9	3.9	4.4	22
Kidney	3.5	3.0	3.3	31	Brain/Nervous System	5.4	5.5	6.7 ▲	26	Liver	4.1	3.6	3.2	15
Myeloma	3.1	2.9	2.9	26	Kidney	5.1	4.4	5.4	22	Urinary Bladder	2.0	2.1	2.1	11
Oral Cavity/Throat	2.5	2.3	2.4	23	Oral Cavity/Throat	3.9	3.5	3.8	16	Myeloma	2.5	2.3	2.1	11
Melanoma of the Skin	2.1	2.0	2.2	19	Myeloma	3.9	3.6	3.7	15	Kidney	2.2	1.9	1.7	8
Stomach	2.8	2.9	2.1 ▼ ▼	18	Stomach	3.8	3.9	3.0	12	Esophagus	1.4	1.5	1.6	8
Larynx	0.9	0.8	0.8	8	Melanoma of the Skin	3.1	2.9	3.0	12	Melanoma of the Skin	1.3	1.3	1.6	7
Thyroid	0.5	0.5	0.5	5	Larynx	1.6	1.5	1.4	7	Cervix	2.2	1.7	1.5	6
Hodgkin Lymphoma	0.3	0.3	0.2	2	Thyroid	0.5	0.5	0.7	3	Oral Cavity/Throat	1.4	1.2	1.3	6
					Testis	0.3	0.2	--	<1	Stomach	2.1	2.0	1.3 ▼	6
					Hodgkin Lymphoma	0.3	0.3	--	<1	Thyroid	0.5	0.5	0.4	2
										Larynx	0.3	0.3	0.3	2
										Hodgkin Lymphoma	0.2	0.2	0.2	1

▲ Statistically higher than the U.S. rate. ▲ Statistically higher than the N.E. rate.
▼ Statistically lower than the U.S. rate. ▼ Statistically lower than the N.E. rate.

TECHNICAL NOTES: Rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population (19 age groups – Census P25–1130) and exclude basal cell and squamous cell skin cancers. Mortality data were coded using the International Classification of Disease Tenth Revision (ICD-10) coding system. Vermont deaths include Vermont residents only. – Rates based on 5 or fewer deaths are not individually calculated. The Vermont and the U.S. mortality rates are based on the Vermont Vital Statistics System, Vermont Department of Health (1994-2020) and the Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2020) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released June 2023. Underlying mortality data provided by NCHS (www.cdc.gov/nchs). Northeast Region (N.E.) includes Connecticut, Maine, Massachusetts, New Hampshire, New York, Pennsylvania, Rhode Island, and Vermont.

COPYRIGHT INFORMATION: All material in this report is in the public domain and may be reproduced or copied without permission. Citation as to source is appreciated. This document can be made available in other accessible formats.

SUGGESTED CITATION: Age Adjusted Cancer Mortality Rates, 2016-2020, Vermont Department of Health, Burlington, VT, 2023.

ACKNOWLEDGEMENT: This publication was supported by the Grant or Cooperative Agreement NU58DP007149, funded by the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention or the Department of Health and Human Services.